Efficacy of dupilumab in the treatment of COPD with type 2 inflammation: A real-world study

The real-world study on efficacy and safety of dupilumab in chronic obstructive pulmonary disease (COPD)with type 2 inflammation are scarce. Our objective was to assess the impact of dupilumab in such patients within a real-world setting. Seventeen patients with COPD and type 2 inflammation, who underwent triple inhaled therapy in conjunction with dupilumab from January 2020 to October 2023, comprised the research group. Similarly, another 17 patients with COPD and type 2 inflammation, who received only triple inhaled therapy, were included in the control group. After a six-month treatment period, pulmonary function tests, type 2 inflammatory marker levels, and quality of life assessments were compared between the two groups to evaluate the effectiveness of dupilumab in combination with triple inhaled therapy for COPD with type 2 inflammation. Following treatment, the research group exhibited significant improvements in forced expiratory volume in 1 s (FEV1) and forced expiratory flow between 25 % and 75 % of forced vital capacity (FVC) compared to the control group ( P < 0.05). Notably, the FEV1 and FVC values of the research group were also notably superior to those of the control group post-treatment ( P < 0.05). Additionally, the research group demonstrated a statistically significant enhancement in COPD Assessment Test scores after treatment ( P < 0.05). The combination of dupilumab with triple inhaled therapy has been shown to enhance pulmonary function, decrease immunoglobulin E levels, manage airway inflammation, and elevate the quality of life of patients with COPD and type 2 inflammation.